Explore more about: COVID-19

The COVID-19 Test Us program was conceived soon after the RADx launch in April to facilitate clinical studies for testing technologies in the real-word setting.

NIH, working in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), today announced a third round of contract awards for scale-up and manufacturing of new COVID-19 testing technologies.

NIH has awarded seven contracts to companies and academic institutions to develop digital health solutions that help address the COVID-19 pandemic.

NIH announced $129.3 million in scale-up and manufacturing support for a new set of COVID-19 testing technologies as part of RADx. These tests add to initial awards made to seven companies on July 31, 2020.

The National Institutes of Health has launched an ambitious effort to use artificial intelligence, computation, and medical imaging to enable early disease detection, inform successful treatment strategies, and predict individual disease outcomes of COVID-19.

NIH is investing $248.7 million in new technologies to address challenges associated with COVID-19 testing (which detects SARS-CoV-2 coronavirus). NIH’s RADx initiative has awarded contracts to seven biomedical diagnostic companies to support a range of new lab-based and point-of-care tests.

In a paper in the New England Journal of Medicine, scientific leaders from the National Institutes of Health set forth a framework to increase significantly the number, quality and type of daily tests for detecting SARS-CoV-2, the virus that causes COVID-19, and help reduce inequities for underserved populations that have been disproportionally affected by the disease.

To help the world respond to COVID-19, 3M and researchers at MIT are testing a new rapid test that detects the virus. Accelerated research is underway to learn if a simple-to-use, diagnostic device can produce highly accurate results within minutes and is feasible to mass manufacture.

Read more here.

Using DNA origami as a virus-like scaffold, researchers designed an HIV-like particle that provokes a strong response from human immune cells grown in the lab. They are now testing this approach as a potential vaccine candidate in live animals, and adapting it to SARS-CoV-2, as well as other pathogens.

NIH has announced a new initiative aimed at speeding innovation, development and commercialization of COVID-19 testing technologies, a pivotal component needed to return to normal during this unprecedented global pandemic.